Insilico’s latest deal is a $120M cardiometabolic drug discovery pact with Qilu Pharma
Insilico Medicine is having quite a month. Fresh from deals with Servier and Hygtia Therapeutics, the biotech has signed a new collaboration with Shanghai-based Qilu Pharmaceutical worth nearly ...
⚠️ 风险分析 中
摘要：中美生物技术合作涉及出口管制与知识产权风险，需关注合规审查。
影响：企业若涉及敏感技术或数据跨境转移，可能面临美国出口管制法规限制，影响合作进展与市场准入。
建议：建议评估技术出口分类，加强知识产权保护协议，并咨询法律专家确保跨境合作合规。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.